Jaime Valdés-Céspedes

#Hematologist 🇨🇴 #InstitutoNacionaldeCancerología #HSCT #BMT #MPN #CML #MM

[Philipp Lahm @philipplahm]

🎄✨ Frohe Weihnachten von der Familie Lahm.
Wir wünschen euch entspannte Feiertage und eine schöne Zeit mit euren Liebsten.

🎄✨ Merry Christmas from the Lahm family.
We wish you relaxing holidays and a wonderful time with your loved ones.

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

🚨 This is it people … you heard it first at #ASH25 🚨
ELN #MRD 205 guidelines are in press in @BloodPortfolio
Bad news: It’s more complicated than before… 🤯
Good news: there’s an app for it 😉
https://t.co/S0p6gDIQmk

[Dr. Nikhil Agrawal @DrNikhilMD]

1️⃣ Start with the fundamental question

Perioperative AC is about preventing two dangers
• Surgical bleeding
• Thrombosis when AC is stopped
Every patient needs BOTH risks assessed before making any move.

[GT_EnfermedadTromboembolica #17ETVSEMI @GT_Trombo]

🏆 PREMIO AL MEJOR ARTÍCULO

Este artículo hace recomendaciones con infografía #hilo46SEMI

📍 Se recomienda la suspensión de la anticoagulación a los 3 meses tras un primer episodio de la ETV provocada por un FR transitorio mayor resuelto si el paciente está asintomático

[Blood Journals Portfolio @BloodPortfolio]

Atezolizumab consolidation in high-risk patients with DLBCL raised 2-year DFS to 87.9% and OS to 96.3%, surpassing historical outcomes. https://t.co/A2h9nl5KPA #clinicaltrialsandobservations #lymphoidneoplasia

[Eric Topol @EricTopol]

Just published @ScienceMagazine
Engineering T cells within the body, a big step forward for treating cancer and autoimmune diseases, as demonstrated in animal models
https://t.co/AGt4Bxhw9e
https://t.co/a0qjSdmEAX

[EBMT @TheEBMT]

👀 Have you read this publication?
📰 Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee ⬇️
https://t.co/Rgs4flozkC

#CAR_T #cellulartherapy #GvHD #medicalresearch

[NEJM Evidence @NEJMEvidence]

𝐉𝐮𝐬𝐭 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝!

Original Article: “An Individualized Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma” by A.M. Rodday (@AngieRodday) et al. https://t.co/zuxJTV8jxG

@DrAEvens @TuftsMedicalCtr @TuftsMCResearch @RutgersCancer @RWJBarnabas @icmlugano #18ICML

[Dr. Chokri Ben Lamine @abouabdrahman0]

🧬 #ICML18 | Role of Auto/Allo-HCT in Burkitt Lymphoma (EBMT Registry)
👨‍⚕️ By Dr. Lorenzo Falchi, Dr. Aljurf et al.

⸻

🔹 Background
•HCT not routinely used 1st-line in Burkitt lymphoma (BL)
•r/r BL has poor prognosis 🧨
•Auto-HCT: bridge or remission deepening
•Allo-HCT: typically in CR≥2
•📉 Limited, outdated data on HCT in BL

⸻

👥 Patient Characteristics (N=1200)
•Auto-HCT: n=958 | Allo-HCT: n=242
•CR1/PR1 at transplant: 61%
•Time to HCT longer in Allo (9.4 mo) vs Auto (7 mo) ⏳
•Allo-HCT had higher rates of no response (37%)
•Median age: Allo 37.6y vs Auto 42y
•23% of Allo were post-Auto salvage

⸻

🧪 Conditioning (Auto-HCT)
•🧱 Most common: BEAM-like (69%)
•Bu-based in 6%, TBI in 10.2%
•Thiotepa-containing: 9.3% overall
 → More frequent in CR2/PR2 (16.1%) vs CR1 (7.3%)

⸻

📈 Median Follow-up
•Overall: 5 years
•CR1/Auto: 5.4y
•CR2/Allo: 7.4y ⬆️
•No response/Allo: 3.1y
•Note: Follow-up censored at 3 years due to heterogeneity

⸻

📎 Conclusion coming soon (pending outcome & survival slides)
#BurkittLymphoma #StemCellTransplant #AutoHCT #AlloHCT #EBMT #ICML2025

[Lymphoma Hub @lymphomahub]

CONGRESS | #18ICML | PRESENTATION
Kate Cwynarski @CwynKate @uclh presents 7-year follow-up results from the phase II MARIETTA trial of multi-agent chemotherapy with MATRix and R-ICE followed by TT-ASCT in patients with SCNSL (N = 75).
Long-term follow-up results demonstrate durable remissions (7-year PFS, 64%) in patients who proceeded to TT-ASCT. The 7-year PFS rates were 52%, 33%, and 11% for patients with de novo SCNSL, isolated CNS relapse, and synchronous CNS relapse, respectively.
Follow our live feed for more updates: https://t.co/OURRpCKwai
#lymphoma #lymsm #MedicalCongress

[Fernando Martín Moro @Fer_martinmoro]

🚨 POTENTIAL NEW SOC IN R/R FOLLICULAR #LYMPHOMA!!

PFS superiority of Tafasitamab-R2 against Placebo-R2 (inMIND phase 3 trial) 📈

Besides, almost all relapses were CD19+ (thus, subsequent CAR-T access is not compromised)

Presented by Dr L Sehn at #ICML2025 #18ICML @icmlugano

[Lymphoma Hub @lymphomahub]

CONGRESS | #18ICML | PRESENTATION
Paul Barr shares the final analysis from the phase II CAPTIVATE study of fixed-duration ibrutinib plus venetoclax for CLL/SLL. 5-year PFS in total cohort 66% and in del(17p)/TP53 mutations 36%. OS in total cohort 97%. After 5.5 years PD observed in 32%. 73% of patients remained treatment free from next-line treatment.
Follow our live feed for more updates: https://t.co/OURRpCKwai
#lymphoma #lymsm #MedEd #MedNews

[Lymphoma Hub @lymphomahub]

CONGRESS | #18ICML | PRESENTATION
Pier Luigi Zinzani shares the results from the ECHO trial, with a focus on MRD with bendamustine-rituximab ± acalabrutinib in patients with previously untreated #MantleCellLymphoma. Achieving MRD negativity was associated with improved PFS, OS, and was a stronger prognostic indicator of outcomes than response. TP53 mutation was a risk factor for MRD positivity.
Follow our live feed for more updates: https://t.co/OURRpCKwai
#lymphoma #lymsm #MedEd #MedNews

[Laura Korin @laura_korin]

Current algorithm for younger and older patients with MCL and potential practice changing studies ongoing. #ICML2025 #ICML18

[Blood Journals Portfolio @BloodPortfolio]

TP53-mutated acute myeloid leukemia and myelodysplastic syndrome are now well established as their own unique diagnostic entity, characterized by an exceptionally poor prognosis and inadequate therapeutic options. https://t.co/p2dD8JoRZI #BloodSpotlight #myeloidneoplasia

[Blood Cancer Discovery @BCD_AACR]

Review: Immune Escape of Acute Myeloid Leukemia after Transplantation https://t.co/w2siG6IpDC

[Blood Cancer Discovery @BCD_AACR]

Cancer Hallmarks Reviews: The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms by #MyeloidMalignancies25 organizer Iannis Aifantis https://t.co/L0KrdJYEJA

[David Gómez-Almaguer @dgomezalmaguer]

Los pacientes mexicanos necesitan CAR-T. Aunque debimos recibir respuesta hace 3 meses, llevamos 6 meses esperando aprobación de @COFEPRIS para iniciar ensayos clínicos en pacientes. Nosotros listos para iniciar!

[All.Can Colombia @AllCanColombia]

Comisión Accidental de seguimiento al Cáncer: un hito para mejorar el panorama de la salud en Colombia.

El 24 de abril desde All.Can acompañamos la instalación de la Comisión Accidental para el seguimiento al Cáncer en Colombia, que tendrá como finalidad revisar y dar recomendaciones para la mejora en el acceso, diagnóstico y tratamiento oportuno.

Este es un paso histórico hacia un sistema más eficiente, justo y centrado en los pacientes.

A continuación les contamos algunos puntos clave de la instalación de la Comisión:

[ASH @ASH_hematology]

🧪 Atypical lymphocytosis: reactive or malignant?

Drs. Courville and Pozdnyakova share a hematopathologist’s approach to this diagnostic challenge—morphology, context, and when to test.

🔗https://t.co/TnEQ6oFsVY

#Hematology #MedTwitter